Analysts Anticipate Intersect ENT Inc (XENT) Will Announce Quarterly Sales of $27.58 Million

Equities research analysts expect that Intersect ENT Inc (NASDAQ:XENT) will post sales of $27.58 million for the current quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Intersect ENT’s earnings. The highest sales estimate is $28.00 million and the lowest is $26.48 million. Intersect ENT posted sales of $24.23 million in the same quarter last year, which would indicate a positive year over year growth rate of 13.8%. The firm is scheduled to announce its next earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Intersect ENT will report full-year sales of $27.58 million for the current financial year, with estimates ranging from $91.70 million to $94.80 million. For the next financial year, analysts forecast that the firm will report sales of $113.03 million per share, with estimates ranging from $108.88 million to $118.17 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Intersect ENT.

Intersect ENT (NASDAQ:XENT) last announced its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The business had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. During the same quarter in the prior year, the firm earned ($0.22) earnings per share. The business’s quarterly revenue was up 20.8% compared to the same quarter last year.

A number of research analysts have issued reports on XENT shares. BidaskClub raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Saturday, December 30th. Zacks Investment Research raised shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a report on Thursday, October 5th. BTIG Research reaffirmed a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Northland Securities reaffirmed a “hold” rating and issued a $25.00 target price on shares of Intersect ENT in a report on Friday, November 3rd. Finally, Canaccord Genuity increased their target price on shares of Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a report on Wednesday, September 13th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Intersect ENT currently has a consensus rating of “Buy” and an average price target of $33.38.

Shares of Intersect ENT (XENT) traded down $0.45 on Thursday, hitting $34.35. 353,600 shares of the stock traded hands, compared to its average volume of 594,750. Intersect ENT has a twelve month low of $11.75 and a twelve month high of $35.10. The firm has a market capitalization of $1,025.06, a P/E ratio of -54.52 and a beta of 0.67.

In other news, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $28.37, for a total value of $567,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lisa D. Earnhardt sold 10,685 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $31.87, for a total transaction of $340,530.95. Following the completion of the sale, the insider now directly owns 487,868 shares of the company’s stock, valued at approximately $15,548,353.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 114,051 shares of company stock worth $3,453,543. 13.70% of the stock is owned by company insiders.

Several large investors have recently made changes to their positions in the stock. Legal & General Group Plc grew its position in shares of Intersect ENT by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 255 shares during the last quarter. Voya Investment Management LLC boosted its stake in Intersect ENT by 9.7% during the 2nd quarter. Voya Investment Management LLC now owns 12,724 shares of the medical equipment provider’s stock valued at $356,000 after purchasing an additional 1,128 shares during the period. Rhumbline Advisers boosted its stake in Intersect ENT by 5.9% during the 2nd quarter. Rhumbline Advisers now owns 29,396 shares of the medical equipment provider’s stock valued at $822,000 after purchasing an additional 1,625 shares during the period. EAM Investors LLC boosted its stake in Intersect ENT by 1.1% during the 3rd quarter. EAM Investors LLC now owns 164,267 shares of the medical equipment provider’s stock valued at $5,117,000 after purchasing an additional 1,776 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in Intersect ENT by 4.4% during the 3rd quarter. Nationwide Fund Advisors now owns 56,901 shares of the medical equipment provider’s stock valued at $1,772,000 after purchasing an additional 2,377 shares during the period. 86.31% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/04/analysts-anticipate-intersect-ent-inc-xent-will-announce-quarterly-sales-of-27-58-million.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply